Strategic Priorities - Pfizer's strategic priorities for 2026 include maximizing the value of key transactions[6] - Delivering on critical R&D milestones is another key priority for Pfizer[6] - Pfizer aims to invest to maximize post-2028 growth[6] - Scaling AI across the business is a strategic priority for Pfizer[6] Pipeline Catalysts - HYMPAVZI (marstacimab) for Hemophilia A/B with Inhibitors has been approved[7] - Regulatory decisions and data readouts are expected for over 20 pivotal study starts[8] - Pfizer is conducting 10 studies on Ultra-Long-Acting GLP-1 (PF'3944 / MET-097i)[8, 9] - Pfizer is conducting 4 studies on PD-1xVEGF (PF'4404)[8, 10] - Pfizer is conducting 2 studies on NURTEC (rimegepant)[8]